Carisma Therapeutics (NASDAQ:CARM) Trading Down 2%

Carisma Therapeutics, Inc. (NASDAQ:CARM)’s share price fell 2% during mid-day trading on Monday . The company traded as low as $0.96 and last traded at $0.96. 87,250 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 382,691 shares. The stock had previously closed at $0.98.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Carisma Therapeutics in a research report on Wednesday, June 26th.

Carisma Therapeutics Price Performance

The firm has a fifty day moving average of $1.05 and a 200 day moving average of $1.42. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 1.39. The company has a market capitalization of $39.89 million, a P/E ratio of -0.48 and a beta of 1.50.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. The firm had revenue of $9.20 million during the quarter, compared to analyst estimates of $3.65 million. Carisma Therapeutics had a negative net margin of 350.08% and a negative return on equity of 344.89%. On average, equities research analysts anticipate that Carisma Therapeutics, Inc. will post -1.43 EPS for the current year.

Hedge Funds Weigh In On Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Carisma Therapeutics, Inc. (NASDAQ:CARM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,006 shares of the company’s stock, valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. owned 0.06% of Carisma Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.